LONDON, April 24 (Reuters) - British pharmaceutical company Clinigen Group said it would become a leader in the supply of unlicensed medicines to doctors and hospitals with the acquisition of Idis for 225 million pounds ($340 million).
from Reuters: New Issues News http://ift.tt/1I2Wdsh
Tidak ada komentar:
Posting Komentar